Additive clinical impact of epidermal growth factor receptor and podocalyxin-like protein expression in pancreatic and periampullary adenocarcinomas

[1]  R. Weinberg,et al.  Epithelial-Mesenchymal Transition Induces Podocalyxin to Promote Extravasation via Ezrin Signaling , 2018, Cell reports.

[2]  M. Uhlén,et al.  Translational study reveals a two-faced role of RBM3 in pancreatic cancer and suggests its potential value as a biomarker for improved patient stratification , 2017, Oncotarget.

[3]  Harri Mustonen,et al.  PROX1 and β-catenin are prognostic markers in pancreatic ductal adenocarcinoma , 2016, BMC Cancer.

[4]  M. Uhlén,et al.  Significant association and synergistic adverse prognostic effect of podocalyxin-like protein and epidermal growth factor receptor expression in colorectal cancer , 2016, Journal of Translational Medicine.

[5]  K. Jirström,et al.  Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1, 2 and 3 in Periampullary Adenocarcinoma , 2016, PloS one.

[6]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[7]  O. Nilsson,et al.  Podocalyxin Is a Marker of Poor Prognosis in Pancreatic Ductal Adenocarcinoma , 2015, PloS one.

[8]  K. Jirström,et al.  Prognostic and predictive significance of podocalyxin-like protein expression in pancreatic and periampullary adenocarcinoma , 2015, BMC Clinical Pathology.

[9]  M. Uhlén,et al.  Reduced Expression of the Polymeric Immunoglobulin Receptor in Pancreatic and Periampullary Adenocarcinoma Signifies Tumour Progression and Poor Prognosis , 2014, PloS one.

[10]  M. Uhlén,et al.  Prognostic and treatment predictive significance of SATB1 and SATB2 expression in pancreatic and periampullary adenocarcinoma , 2014, Journal of Translational Medicine.

[11]  M. Hoque,et al.  The TGFβ-miR200-MIG6 pathway orchestrates the EMT-associated kinase switch that induces resistance to EGFR inhibitors. , 2014, Cancer research.

[12]  K. Jirström,et al.  Use of a standardized diagnostic approach improves the prognostic information of histopathologic factors in pancreatic and periampullary adenocarcinoma , 2014, Diagnostic Pathology.

[13]  Donghui Li,et al.  Biomarkers of TGF-β Signaling Pathway and Prognosis of Pancreatic Cancer , 2014, PloS one.

[14]  O. Nilsson,et al.  Podocalyxin is a marker of poor prognosis in colorectal cancer , 2014, BMC Cancer.

[15]  H. Moses,et al.  The roles of TGFβ in the tumour microenvironment , 2013, Nature Reviews Cancer.

[16]  Zev A. Binder,et al.  Podocalyxin-Like Protein Is Expressed in Glioblastoma Multiforme Stem-Like Cells and Is Associated with Poor Outcome , 2013, PloS one.

[17]  T. Keck,et al.  Intestinal-type of differentiation predicts favourable overall survival: confirmatory clinicopathological analysis of 198 periampullary adenocarcinomas of pancreatic, biliary, ampullary and duodenal origin , 2013, BMC Cancer.

[18]  M. Uhlén,et al.  Podocalyxin-like protein expression in primary colorectal cancer and synchronous lymph node metastases , 2013, Diagnostic Pathology.

[19]  M. Uhlén,et al.  Membranous expression of podocalyxin-like protein is an independent factor of poor prognosis in urothelial bladder cancer , 2013, British Journal of Cancer.

[20]  M. Vijver,et al.  HER2 testing in gastric cancer: a practical approach , 2012, Modern Pathology.

[21]  L. Bujanda,et al.  Adjuvant and neoadjuvant treatment in pancreatic cancer. , 2012, World journal of gastroenterology.

[22]  M. Uhlén,et al.  Validation of podocalyxin-like protein as a biomarker of poor prognosis in colorectal cancer , 2012, BMC Cancer.

[23]  M. Köbel,et al.  The anti-adhesive mucin podocalyxin may help initiate the transperitoneal metastasis of high grade serous ovarian carcinoma , 2012, Clinical & Experimental Metastasis.

[24]  K. Jirström,et al.  Overexpression of podocalyxin-like protein is an independent factor of poor prognosis in colorectal cancer , 2011, British Journal of Cancer.

[25]  J. Wilkins,et al.  Requirement of Podocalyxin in TGF-Beta Induced Epithelial Mesenchymal Transition , 2011, PloS one.

[26]  A. Siriwardena,et al.  Epidermal Growth Factor Receptor in Pancreatic Cancer , 2011, Cancers.

[27]  G. Thomas,et al.  Cell migration and invasion assays. , 2011, Methods in molecular biology.

[28]  H. Kocher,et al.  Pancreatic cancer organotypic cultures. , 2010, Journal of biotechnology.

[29]  J. Shea,et al.  Phenotype and Genotype of Pancreatic Cancer Cell Lines , 2010, Pancreas.

[30]  O. Clausen,et al.  Pancreatobiliary versus intestinal histologic type of differentiation is an independent prognostic factor in resected periampullary adenocarcinoma , 2008, BMC Cancer.

[31]  S. Thomson,et al.  Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions , 2008, Clinical & Experimental Metastasis.

[32]  P. Murawa,et al.  Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  中島 早苗.  N-cadherin expression and epithelial mesenchymal transition in pancreatic carcinoma , 2007 .

[34]  A. Miyajima,et al.  Podocalyxin is a CD34-related marker of murine hematopoietic stem cells and embryonic erythroid cells , 2005 .

[35]  D. Lauffenburger,et al.  The Na+/H+ exchanger regulatory factor stabilizes epidermal growth factor receptors at the cell surface. , 2004, Molecular biology of the cell.

[36]  D. Huntsman,et al.  Overexpression of the Anti-Adhesin Podocalyxin Is an Independent Predictor of Breast Cancer Progression , 2004, Cancer Research.

[37]  Hidetaka Mochizuki,et al.  The Correlation Between Cytoplasmic Overexpression of Epidermal Growth Factor Receptor and Tumor Aggressiveness: Poor Prognosis in Patients With Pancreatic Ductal Adenocarcinoma , 2004, Pancreas.

[38]  M. Imamura,et al.  N-Cadherin Expression and Epithelial-Mesenchymal Transition in Pancreatic Carcinoma , 2004, Clinical Cancer Research.

[39]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[40]  J. Abbruzzese,et al.  Epidermal growth factor receptor-targeted therapy for pancreatic cancer. , 2002, Seminars in oncology.

[41]  Yong Li,et al.  PDZ domain-mediated interaction of rabbit podocalyxin and Na(+)/H(+) exchange regulatory factor-2. , 2002, American journal of physiology. Renal physiology.

[42]  H. Moch,et al.  Tissue microarrays for rapid linking of molecular changes to clinical endpoints. , 2001, The American journal of pathology.

[43]  Allan Balmain,et al.  TGF-β signaling in tumor suppression and cancer progression , 2001, Nature Genetics.

[44]  C. Arteaga.  The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  T. Graf,et al.  Anuria, Omphalocele, and Perinatal Lethality in Mice Lacking the Cd34-Related Protein Podocalyxin , 2001, The Journal of experimental medicine.

[46]  A. Balmain,et al.  TGF-beta signaling in tumor suppression and cancer progression. , 2001, Nature genetics.

[47]  R. Wallace.  Is this a practical approach? , 2001, Journal of the American College of Surgeons.

[48]  G. Klöppel,et al.  The K‐ras mutation pattern in pancreatic ductal adenocarcinoma usually is identical to that in associated normal, hyperplastic, and metaplastic ductal epithelium , 1999, Cancer.

[49]  M. Mann,et al.  Thrombomucin, a Novel Cell Surface Protein that Defines Thrombocytes and Multipotent Hematopoietic Progenitors , 1997, The Journal of cell biology.

[50]  Scott E. Kern,et al.  DPC4, A Candidate Tumor Suppressor Gene at Human Chromosome 18q21.1 , 1996, Science.

[51]  R. Derynck,et al.  TGF-beta induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors , 1994, The Journal of cell biology.

[52]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[53]  G. Dekan,et al.  Endothelial cell membranes contain podocalyxin--the major sialoprotein of visceral glomerular epithelial cells , 1986, The Journal of cell biology.

[54]  D. Kerjaschki,et al.  Identification and characterization of podocalyxin--the major sialoprotein of the renal glomerular epithelial cell , 1984, The Journal of cell biology.